Abstract 3811
Background
LUR is a new agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical synergism/additivity in combination with IRI has been reported, thus prompting the conduct of this trial.
Methods
Phase I trial to evaluate escalating doses of LUR on Day (D) 1 plus a fixed dose of IRI 75 mg/m2 on D1 and D8 every 3 weeks (q3w) in pts with advanced solid tumors, enrolled following a standard 3 + 3 dose escalation design.
Results
39 pts were treated at 5 dose levels (DL); 13 at the recommended dose (RD). 56% were females, 69% had ECOG PS = 1; median age was 58 years; median of 2 prior chemotherapy lines for advanced disease (range, 0 − 4) per pt. RD was defined as LUR 2.0 mg/m2 on D1 + IRI 75 mg/m2 on D1 and D8 q3w + GCSF. Dose-limiting toxicities in Cycle 1 were observed in 2/3 evaluable pts at the maximum tolerated dose (MTD) and in 3/13 evaluable pts at the RD. At the MTD and the RD, DLTs were skipping IRI D8 doses due to grade (G) 3-4 neutropenia (n = 3 patients) or G2-4 thrombocytopenia (n = 2). At the RD common G1/2 toxicities were nausea, vomiting, fatigue, diarrhea, anorexia and neuropathy; G3/4 hematological abnormalities comprised neutropenia (33%), but no thrombocytopenia. Objective RECIST responses were documented in 6/34 evaluable pts (18%): 3/11 pts with small cell lung cancer (SCLC), 2/2 pts with endometrial carcinoma (EC) and 1/3 pts with glioblastoma (GB). Most responses (5/12 evaluable patients [42%]) were at the RD. One pt with EC has an ongoing PR after 20 cycles. Prolonged SD > 4 months were observed in pancreatic carcinoma (3/6 pts), soft tissue sarcoma (STS) (5/9 pts) and SCLC (6/11, including 4 with SD for 6, 9, 11 and 26+ months).
Conclusions
The combination of LUR and IRI is well tolerated, with no unexpected toxicities. Myelosuppression was dose-limiting, but predictable and manageable. The RD is LUR 2.0 mg/m2 on D1 + IRI 75 mg/m2 on D1 and D8 q3w with GCSF. Notable antitumor activity was observed, especially in SCLC, EC, GB and STS. Expansion in these indications is warranted.
Clinical trial identification
NCT02611024.
Editorial acknowledgement
Legal entity responsible for the study
PharmaMar SA.
Funding
PharmaMar.
Disclosure
S. Ponce Aix: Advisory / Consultancy: Roche; Speaker Bureau / Expert testimony: Roche, BMS, MSD. G. Coté: Advisory / Consultancy: Agios; Research grant / Funding (institution), Research funding to my institution for the conduct of clinical trials; no salary support: Epizyme, Eisai, Macrogenics, Boston Biomedical, Plexxicon, Merck KGaA/EMD Serono Research and Development Institute, CBA Inc, Bayer. R. Nuñez: Shareholder / Stockholder / Stock options, Full / Part-time employment: PharmaMar. M. Siguero: Shareholder / Stockholder / Stock options, Full / Part-time employment: PharmaMar. M. Insa: Full / Part-time employment: PharmaMar. M. Cullell-Young: Shareholder / Stockholder / Stock options, Full / Part-time employment: PharmaMar. C. Kahatt: Shareholder / Stockholder / Stock options, Full / Part-time employment: PharmaMar. A. Zeaiter: Shareholder / Stockholder / Stock options, Full / Part-time employment: PharmaMar. L. Paz-Ares: Advisory / Consultancy: Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; MSD; Novartis; Pfizer; Roche; Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
860 - Dose differential modulation of the autophagic behavior of estrogen expressing breast carcinoma cells
Presenter: Mariam Fouad
Session: Poster Display session 1
Resources:
Abstract
2304 - Synthetic peptide of tumor–associated antigen L6 formulated with polymer-based adjuvant enhances anti-tumor effects in mice
Presenter: Shih-jen Liu
Session: Poster Display session 1
Resources:
Abstract
4419 - Improving detection level of somatic mosaicism in neurofibromatosis type 1
Presenter: Kristina Karandasheva
Session: Poster Display session 1
Resources:
Abstract
5283 - Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship of ABN401, a highly selective Met inhibitor, in gastric and non-small-cell lung cancer models
Presenter: JooSeok Kim
Session: Poster Display session 1
Resources:
Abstract
5488 - Transcription factors of Snail family in the regulation of resistance of breast cancer cells to hypoxic conditions
Presenter: Alvina Khamidullina
Session: Poster Display session 1
Resources:
Abstract
5417 - Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumour cells
Presenter: Liliana Mendonça
Session: Poster Display session 1
Resources:
Abstract
5494 - Identification of novel and known FGFR gene fusions in Chinese non-small cell lung cancer
Presenter: Weixin Zhao
Session: Poster Display session 1
Resources:
Abstract
3412 - WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients.
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 1
Resources:
Abstract
1815 - Leukocytosis as a negative prognostic factor in patients with lung cancer: Which subpopulation of leukocytes is responsible?
Presenter: Filip Kohutek
Session: Poster Display session 1
Resources:
Abstract
5022 - Identification of MET gene amplifications using next-generation sequencing in non-small cell lung cancer patients
Presenter: Sergi Clavé
Session: Poster Display session 1
Resources:
Abstract